Nasdaq

4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from ...
Nasdaq

4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from ...
Forbes

$6.16 Billion Per Drug Approval: Almost Half of Big Pharma Companies Hit Negative R&D Productivity

Steven Paul’s “How to improve R&D productivity: the pharmaceutical industry's grand challenge” published in Nature Reviews Drug Discovery in 2010 is one of the highest cited and most frequently quoted ...
Business Wire

4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from ...